 | | Cardiovascular Exchange Summit 2011 |
|  | | Cardiovascular mortality in haemodialysis patients |
|
 | | Causes of death in dialysis patients |
|  | | Serum cholesterol and relative risk of death |
|
 | | Proportional effects on MAJOR VASCULAR EVENTS |
|  | | SHARP: Rationale |
|
 | | SHARP: Eligibility |
|  | | SHARP: Assessment of LDL-lowering |
|
 | | SHARP: Main outcomes |
|  | | SHARP: Baseline characteristics |
|
 | | RENAL STATUS |
|  | | LIPID PROFILE at initial randomization |
|
 | | SHARP: Compliance and LDL-C reduction at study midpoint |
|  | | SHARP: Compliance and LDL-C reduction at study midpoint |
|
 | | SHARP: Major Atherosclerotic Events |
|  | | CTT: Effects on Major Atherosclerotic Events |
|
 | | CTT: Effects on Major Atherosclerotic Events |
|  | | CTT: Effects on Major Atherosclerotic Events |
|
 | | SHARP: Major Atherosclerotic Events |
|  | | SHARP: Cause-specific mortality |
|
 | | SHARP: Renal outcomes |
|  | | SHARP: estimated rate of change in eGFR |
|
 | | SHARP: Cancer incidence |
|  | | SHARP: Safety |
|
 | | SHARP: Conclusions |
|
Deel deze pagina met collega's en vrienden: